J&J to launch newest JLABS incubator in NYC

Armed with $17 million in state funds, Johnson & Johnson hopes to create a home for as many as 30 life science startups.

By Judy Packer-Tursman • Jan. 11, 2017

JPM: A sunny tone despite rain

Executives at a BioPharma Dive-hosted panel discussed the changing tides of M&A. 

By Lisa LaMotta • Jan. 10, 2017

Kite inks China, Japan deals ahead of possible CAR-T drug approval

Through a joint venture with China's Fosun Pharma, the CAR-T specialist gains a foothold for its lead drug candidate in the world's second biggest pharma market.

By Jacob Bell • Jan. 10, 2017

Sanofi, Immunext partner to develop autoimmune therapies

Sanofi has agreed to fork over as much as $500 million in milestone payments to develop the biotech's monoclonal antibody aimed at treating diseases such as lupus and multiple sclerosis.

By Judy Packer-Tursman • Jan. 10, 2017

Allergan partnerships with Assembly Biosciences, Lysosomal target gut bugs and CNS

The deals allow Allergan to expand its pipeline into new therapeutic areas.

By Suzanne Elvidge • Jan. 10, 2017

Celgene locks down option to buy autoimmune drugmaker

The research collaboration agreement gives Celgene — which is eager to diversify its pipeline — the exclusive rights to buy Swiss biotech Anokion.

By Suzanne Elvidge • Jan. 10, 2017

JPM: Valeant sells off Dendreon, skincare brands for $2.1B

Trapped by debt built up under its former 'acquire-and-hike' business strategy, Valeant has been looking to slim down in exchange for some much-needed cash.

By Ned Pagliarulo • Jan. 10, 2017

JPM: Day 1 round-up

The first day of the J.P. Morgan Healthcare Conference started off with a bang as several companies announced deals. 

By Lisa LaMotta • Jan. 9, 2017

Pharma M&A may see 'banner year' in 2017, EY predicts

Consultancy EY anticipates higher pricing pressure and formidable firepower should spur an uptick in M&A over the next year, according to its newly released report.

By Jacob Bell • Jan. 9, 2017

Savara expands pipeline in reverse merger with Mast

Mast began searching for potential partners after shuttering its lead program in the wake of a Phase 3 miss last September.

By Judy Packer-Tursman • Jan. 9, 2017

JPM: Takeda acquires Ariad in $5.2B deal

Takeda has been on the hunt for acquisition targets in the U.S. Ariad fits the bill, but comes with perhaps unwanted scrutiny over the price tag for its main drug. 

By Jacob Bell • Jan. 9, 2017

Novartis hooks up with Ionis for access to CV drugs

Novartis now has the option to boost its cardiometabolic offerings in a deal that could be worth more than $1.6 billion.

By Suzanne Elvidge • Jan. 9, 2017

JPM: Illumina links up with IBM's Watson

The partnership aims to speed the analysis and interpretation of sequencing data created by one of Illumina's tumor profiling panels. 

By Suzanne Elvidge • Jan. 9, 2017

JPM: Ipsen snatches up Merrimack's Onivyde for $575M

Selling its crown jewel, Merrimack will substantially cut its workforce and pivot from commercialization efforts to a new focus on three pipeline assets. 

By Ned Pagliarulo • Jan. 8, 2017

Prescribed Reading: Quiet before the storm

M&A was slow in 2016 and 2017 is off to a slow start. But the JP Morgan conference in San Francisco next week could put dealmaking back in full swing. 

By Lisa LaMotta • Jan. 6, 2017

Tiny startup hooks Takeda in celiac deal

PvP Biologics will get some much-needed cash to fund preclinical work on a therapeutic for celiac disease. 

By Suzanne Elvidge • Jan. 5, 2017

Diet no more: Arena sheds Belviq in Eisai sale

The beleaguered biotech will no longer be weighed down by its failing weight loss drug, getting much-needed cash in a divestment. 

By Lisa LaMotta • Jan. 5, 2017

AstraZeneca taps APT in latest deal

An antithrombotic deal plugs a gap in AstraZeneca's CV pipeline.

By Suzanne Elvidge • Jan. 5, 2017

Is Gilead poised for deal-making?

The big biotech has made a new hire that could mean it is looking to expand its oncology presence in a big way. 

By Lisa LaMotta • Jan. 4, 2017

Tiny Rana makes a play for mRNA with Shire deal

Shire sold rights to its messenger RNA platform in exchange for an equity stake in Cambridge-based Rana Therapeutics. 

By Ned Pagliarulo • Jan. 4, 2017

RedHill, Concordia team up to market IBS drug

Under terms of a new agreement, RedHill will gain some U.S. promotional rights to Concordia's Donnatal.

By Jacob Bell • Jan. 3, 2017

7 takeover targets to look out for in 2017

After a slow 2016, industry followers expect at least a slight uptick in M&A next year as a new president, patent losses and promising markets entice further deals.

By Jacob Bell • Jan. 3, 2017

Report: Positive outlook for big pharma in 2017

At least one analyst believes there will be more catalysts in R&D and an uptick in M&A during the coming year. 

By Lisa LaMotta • Dec. 27, 2016

Prescribed Reading: An uptick in year-end M&A

Several companies are striking deals to round out the year, while others are trying to bury bad data, and the FDA cracks down on manufacturing. 

By Lisa LaMotta • Dec. 23, 2016

Novartis, Sun Pharma enter deal for oncology drug Odomzo

Approved in 2015, Odomzo hasn't been much of a revenue earner for Novartis but should help Sun expand its oncology offerings. 

By Jacob Bell • Dec. 23, 2016